Recruiting PHASE2 INTERVENTIONAL 3-arm NCT06400121

Apimostinel + Automated Neurocognitive Training for Depression

Phase 2, Randomized, Double-Blind, Placebo-Controlled, Single Intravenous Dose, Parallel Efficacy Study of Apimostinel With or Without Subsequent Automated Self-Association Training in Subjects With Major Depressive Disorder

Sponsor: Rebecca Price

Conditions Depression

Interventions Apimostinel Infusion, Intravenous Cognitive Training Isotonic Solution, Intravenous Sham Training

Updated 9 times since 2024 Last updated: Sep 23, 2025 Started: Oct 28, 2024 Primary completion: Mar 1, 2029 Completion: Dec 1, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06400121, this PHASE2 trial focuses on Depression and remains actively recruiting participants. Sponsored by Rebecca Price, it has been updated 9 times since 2024, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

9 versions recorded

Oct 2025 — Present [monthly]

Recruiting PHASE2
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE2
Mar 2025 — Sep 2025 [monthly]

Recruiting PHASE2
Dec 2024 — Mar 2025 [monthly]

Recruiting PHASE2
Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting

▶ Show 4 earlier versions

Oct 2024 — Nov 2024 [monthly]

Not Yet Recruiting PHASE2
Sep 2024 — Oct 2024 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Jun 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Rebecca Price
Syndeio Biosciences, Inc

Data source: University of Pittsburgh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pittsburgh, United States